P/E ratio for Xenon Pharmaceuticals (XENE)
P/E ratio as of April 2024 (TTM): -16.3
According to Xenon Pharmaceuticals's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -16.3112. At the end of 2022 the company had a P/E ratio of -19.3.
P/E ratio history for Xenon Pharmaceuticals from 2014 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -19.3 | 9.51% |
| 2021 | -17.6 | -6.49% |
| 2020 | -18.9 | 120.27% |
| 2019 | -8.57 | 114.56% |
| 2018 | -3.99 | 141.74% |
| 2017 | -1.65 | -68.25% |
| 2016 | -5.20 | -28.82% |
| 2015 | -7.31 | -134.39% |
| 2014 | 21.3 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 Coherus BioSciences
CHRS | -0.6024 | -96.31% | 🇺🇸 USA |
 Atara Biotherapeutics ATRA | -0.2500 | -98.47% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.